Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Sandra Bos, Gilles Gadea & Philippe Despres. (2018) Dengue: a growing threat requiring vaccine development for disease prevention. Pathogens and Global Health 112:6, pages 294-305.
Read now
Read now
Yang Liu, Jianying Liu & Gong Cheng. (2016) Vaccines and immunization strategies for dengue prevention. Emerging Microbes & Infections 5:1, pages 1-6.
Read now
Read now
Sai Kit Lam. (2013) Challenges in reducing dengue burden; diagnostics, control measures and vaccines. Expert Review of Vaccines 12:9, pages 995-1010.
Read now
Read now
Monica A McArthur, Marcelo B Sztein & Robert Edelman. (2013) Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Review of Vaccines 12:8, pages 933-953.
Read now
Read now
Monika Simmons, Nimfa Teneza-Mora & Robert Putnak. (2012) Advances in the development of vaccines for dengue fever. Vaccine: Development and Therapy 2, pages 1-14.
Read now
Read now
Sathyamangalam Swaminathan, Gaurav Batra & Navin Khanna. (2010) Dengue vaccines: state of the art. Expert Opinion on Therapeutic Patents 20:6, pages 819-835.
Read now
Read now
P Noel Barrett, Wolfgang Mundt, Otfried Kistner & M Keith Howard. (2009) Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Review of Vaccines 8:5, pages 607-618.
Read now
Read now
Articles from other publishers (70)
Jessica Pintado Silva & Ana Fernandez-Sesma. (2023) Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art. Journal of General Virology 104:3.
Crossref
Crossref
Stephen J. Thomas, Timothy P. Endy & Alan L. Rothman. 2020. Viral Infections of Humans. Viral Infections of Humans
1
65
.
Jessica Pintado Silva, Rafael Fenutria, Dabeiba Bernal-Rubio, Irene Sanchez-Martin, Annika Hunziker, Eva Chebishev, Jeury Veloz, Geoffrey Kelly, Seunghee Kim-Schulze, Steve Whitehead, Anna Durbin, Irene Ramos & Ana Fernandez-Sesma. (2023) The dengue virus 4 component of NIAID’s tetravalent TV003 vaccine drives its innate immune signature. Experimental Biology and Medicine 247:24, pages 2201-2212.
Crossref
Crossref
Usha K. Nivarthi, Jesica Swanstrom, Matthew J. Delacruz, Bhumi Patel, Anna P. Durbin, Steve S. Whitehead, Beth D. Kirkpatrick, Kristen K. Pierce, Sean A. Diehl, Leah Katzelnick, Ralph S. Baric & Aravinda M. de Silva. (2021) A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Nature Communications 12:1.
Crossref
Crossref
Laura A. VanBlargan, Pavle S. Milutinovic, Leslie Goo, Christina R. DeMaso, Anna P. Durbin, Stephen S. Whitehead, Theodore C. Pierson & Kimberly A. Dowd. (2021) Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera. Journal of Virology 95:23.
Crossref
Crossref
Rita E. Chen, Brittany K. Smith, John M. Errico, David N. Gordon, Emma S. Winkler, Laura A. VanBlargan, Chandni Desai, Scott A. Handley, Kimberly A. Dowd, Emerito Amaro-Carambot, M. Jane Cardosa, Carlos A. Sariol, Esper G. Kallas, Rafick-Pierre Sékaly, Nikos Vasilakis, Daved H. Fremont, Stephen S. Whitehead, Theodore C. Pierson & Michael S. Diamond. (2021) Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host & Microbe 29:11, pages 1634-1648.e5.
Crossref
Crossref
Nina Wressnigg, Romana Hochreiter, Oliver Zoihsl, Andrea Fritzer, Nicole Bézay, Anton Klingler, Karen Lingnau, Martina Schneider, Urban Lundberg, Andreas Meinke, Julian Larcher-Senn, Irena Čorbic-Ramljak, Susanne Eder-Lingelbach, Katrin Dubischar & Wolfgang Bender. (2020) Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. The Lancet Infectious Diseases 20:10, pages 1193-1203.
Crossref
Crossref
Anna P Durbin. (2020) Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005. Current Opinion in Virology 43, pages 79-87.
Crossref
Crossref
Josilene Ramos Pinheiro-Michelsen, Rayane da Silva Oliveira Souza, Itana Vivian Rocha Santana, Patrícia de Souza da Silva, Erick Carvalho Mendez, Wilson Barros Luiz & Jaime Henrique Amorim. (2020) Anti-dengue Vaccines: From Development to Clinical Trials. Frontiers in Immunology 11.
Crossref
Crossref
Nicolas Tremblay, Wesley Freppel, Aïssatou Aïcha Sow & Laurent Chatel-Chaix. (2019) The Interplay between Dengue Virus and the Human Innate Immune System: A Game of Hide and Seek. Vaccines 7:4, pages 145.
Crossref
Crossref
Jesica A Swanstrom, Usha K Nivarthi, Bhumi Patel, Matthew J Delacruz, Boyd Yount, Douglas G Widman, Anna P Durbin, Stephen S Whitehead, Aravinda M De Silva & Ralph S Baric. (2019) Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. The Journal of Infectious Diseases 220:2, pages 219-227.
Crossref
Crossref
Thi Hanh Tien Nguyen, Hannah E. Clapham, Khanh Lam Phung, Thanh Kieu Nguyen, The Trung DInh, Than Ha Quyen Nguyen, Van Ngoc Tran, Stephen Whitehead, Cameron Simmons, Marcel Wolbers & Bridget Wills. (2018) Methods to discriminate primary from secondary dengue during acute symptomatic infection. BMC Infectious Diseases 18:1.
Crossref
Crossref
Stephen J Popper, Fiona R Strouts, Janet C Lindow, Henry K Cheng, Magelda Montoya, Angel Balmaseda, Anna P Durbin, Stephen S Whitehead, Eva Harris, Beth D Kirkpatrick & David A Relman. (2018) Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers. The Journal of Infectious Diseases 218:12, pages 1911-1921.
Crossref
Crossref
José Bustos-Arriaga, Gregory D. Gromowski, Konstantin A. Tsetsarkin, Cai-Yen Firestone, Tannya Castro-Jiménez, Alexander G. Pletnev, Leticia Cedillo-Barrón & Stephen S. Whitehead. (2018) Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon. Vaccine 36:24, pages 3460-3467.
Crossref
Crossref
Scott B. Halstead & Stephen J. Thomas. 2018. Plotkin's Vaccines. Plotkin's Vaccines
241
251.e6
.
Stephen S. Whitehead, Anna P. Durbin, Kristen K. Pierce, Dan Elwood, Benjamin D. McElvany, Ellen A. Fraser, Marya P. Carmolli, Cecilia M. Tibery, Noreen A. Hynes, Matthew Jo, Janece M. Lovchik, Catherine J. Larsson, Elena A. Doty, Dorothy M. Dickson, Catherine J. Luke, Kanta Subbarao, Sean A. Diehl & Beth D. Kirkpatrick. (2017) In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLOS Neglected Tropical Diseases 11:5, pages e0005584.
Crossref
Crossref
Anuradha Balasubramanian, Tadahisa Teramoto, Amol A. Kulkarni, Apurba K. Bhattacharjee & Radhakrishnan Padmanabhan. (2017) Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus. Antiviral Research 137, pages 141-150.
Crossref
Crossref
Laura A. VanBlargan, Leslie Goo & Theodore C. Pierson. (2016) Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiology and Molecular Biology Reviews 80:4, pages 989-1010.
Crossref
Crossref
Vincent Muturi-Kioi, David Lewis, Odile Launay, Geert Leroux-Roels, Alessandra Anemona, Pierre Loulergue, Caroline L. Bodinham, Annelies Aerssens, Nicola Groth, Allan Saul & Audino Podda. (2016) Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. PLOS ONE 11:8, pages e0157385.
Crossref
Crossref
Beth D. KirkpatrickStephen S. WhiteheadKristen K. PierceCecilia M. TiberyPalmtama L. GrierNoreen A. HynesCatherine J. LarssonBeulah P. SabundayoKawsar R. TalaatAnna JaniakMarya P. CarmolliCatherine J. LukeSean A. DiehlAnna P. Durbin. (2016) The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Science Translational Medicine 8:330.
Crossref
Crossref
Taoufik Nedjadi, Sherif El-Kafrawy, Sayed S. Sohrab, Philippe Desprès, Ghazi Damanhouri & Esam Azhar. (2015) Tackling dengue fever: Current status and challenges. Virology Journal 12:1.
Crossref
Crossref
Alexander Roberto Precioso, Ricardo Palacios, Beatriz Thom?Gabriella Mondini, Patr?cia Braga & Jorge Kalil. (2015) Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine. Vaccine 33:50, pages 7121-7125.
Crossref
Crossref
Christian P. Larsen, Stephen S. Whitehead & Anna P. Durbin. (2015) Dengue human infection models to advance dengue vaccine development. Vaccine 33:50, pages 7075-7082.
Crossref
Crossref
Stephen J. Thomas & Alan L. Rothman. (2015) Trials and Tribulations on the Path to Developing a Dengue Vaccine. American Journal of Preventive Medicine 49:6, pages S334-S344.
Crossref
Crossref
Stephen J. Thomas & Alan L. Rothman. (2015) Trials and tribulations on the path to developing a dengue vaccine. Vaccine 33, pages D24-D31.
Crossref
Crossref
Christian P. Larsen, Stephen S. Whitehead & Anna P. Durbin. (2015) WITHDRAWN: Dengue Human Infection Models to Advance Dengue Vaccine Development. Vaccine.
Crossref
Crossref
Beth D. Kirkpatrick, Anna P. Durbin, Kristen K. Pierce, Marya P. Carmolli, Cecilia M. Tibery, Palmtama L. Grier, Noreen Hynes, Sean A. Diehl, Dan Elwood, Adrienne P. Jarvis, Beulah P. Sabundayo, Caroline E. Lyon, Catherine J. Larsson, Matthew Jo, Janece M. Lovchik, Catherine J. Luke, Mary C. Walsh, Ellen A. Fraser, Kanta Subbarao & Steven S. Whitehead. (2015) Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. Journal of Infectious Diseases 212:5, pages 702-710.
Crossref
Crossref
Margo A. Brinton & Mausumi Basu. (2015) Functions of the 3′ and 5′ genome RNA regions of members of the genus Flavivirus. Virus Research 206, pages 108-119.
Crossref
Crossref
Lauren M. Schwartz, M. Elizabeth Halloran, Anna P. Durbin & Ira M. LonginiJr.Jr.. (2015) The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine 33:29, pages 3293-3298.
Crossref
Crossref
Laura L. Hermann, Swati B. Gupta, Susan B. Manoff, Siripen Kalayanarooj, Robert V. Gibbons & Beth-Ann G. Coller. (2015) Advances in the understanding, management, and prevention of dengue. Journal of Clinical Virology 64, pages 153-159.
Crossref
Crossref
Jan ter Meulen, Danilo Casimiro, Beth-Ann Coller, Jon Heinrichs & Akhilesh Bhambhani. 2015. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies
251
287
.
Carlos A. Sariol & Laura J. White. (2014) Utility, Limitations, and Future of Non-Human Primates for Dengue Research and Vaccine Development. Frontiers in Immunology 5.
Crossref
Crossref
Stephen J. Thomas. (2014) Developing a dengue vaccine: progress and future challenges. Annals of the New York Academy of Sciences 1323:1, pages 140-159.
Crossref
Crossref
Jorge E Osorio, Ivan D Velez, Cynthia Thomson, Liliana Lopez, Alejandra Jimenez, Aurelia A Haller, Shawn Silengo, Jaclyn Scott, Karen L Boroughs, Janae L Stovall, Betty E Luy, John Arguello, Mark E Beatty, Joseph Santangelo, Gilad S Gordon, Claire Y-H Huang & Dan T Stinchcomb. (2014) Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. The Lancet Infectious Diseases 14:9, pages 830-838.
Crossref
Crossref
James Whitehorn & Jeremy FarrarMonica A McArthurMarcelo B SzteinRobert Edelman. 2014. Clinical Insights: Dengue: Transmission, Diagnosis & Surveillance. Clinical Insights: Dengue: Transmission, Diagnosis & Surveillance
103
119
.
Lauren E. Yauch & Sujan Shresta. 2014.
315
372
.
Stephen J. Thomas, Timothy P. Endy & Alan L. Rothman. 2014. Viral Infections of Humans. Viral Infections of Humans
351
381
.
Laura A. VanBlargan, Swati Mukherjee, Kimberly A. Dowd, Anna P. Durbin, Stephen S. Whitehead & Theodore C. Pierson. (2013) The Type-Specific Neutralizing Antibody Response Elicited by a Dengue Vaccine Candidate Is Focused on Two Amino Acids of the Envelope Protein. PLoS Pathogens 9:12, pages e1003761.
Crossref
Crossref
Anna P. Durbin, Peter F. Wright, Amber Cox, Wangeci Kagucia, Daniel Elwood, Susan Henderson, Kimberli Wanionek, Jim Speicher, Stephen S. Whitehead & Alexander G. Pletnev. (2013) The live attenuated chimeric vaccine rWN/DEN4?30 is well-tolerated and immunogenic in healthy flavivirus-na?ve adult volunteers. Vaccine 31:48, pages 5772-5777.
Crossref
Crossref
Janet C. Lindow, Anna P. Durbin, Stephen S. Whitehead, Kristen K. Pierce, Marya P. Carmolli & Beth D. Kirkpatrick. (2013) Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine 31:33, pages 3347-3352.
Crossref
Crossref
Scott A. Smith, Ruklanthi de Alwis, Nurgun Kose, Anna P. Durbin, Stephen S. Whitehead, Aravinda M. de Silva & James E. CroweJrJr. (2013) Human Monoclonal Antibodies Derived From Memory B Cells Following Live Attenuated Dengue Virus Vaccination or Natural Infection Exhibit Similar Characteristics. The Journal of Infectious Diseases 207:12, pages 1898-1908.
Crossref
Crossref
Anna P. Durbin, Sandra V. Mayer, Shannan L. Rossi, Irma Y. Amaya-Larios, Jose Ramos-Castaneda, Eng Eong Ooi, M. Jane Cardosa, Jorge L. Munoz-Jordan, Robert B. Tesh, William B. Messer, Scott C. Weaver & Nikos Vasilakis. (2013) Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. Virology 439:1, pages 34-41.
Crossref
Crossref
Anna P. Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Daniel Elwood, Catherine J. Larsson, Janet C. Lindow, Cecilia Tibery, Beulah P. Sabundayo, Donna Shaffer, Kawsar R. Talaat, Noreen A. Hynes, Kimberli Wanionek, Marya P. Carmolli, Catherine J. Luke, Brian R. Murphy, Kanta Subbarao & Stephen S. Whitehead. (2013) A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial. The Journal of Infectious Diseases 207:6, pages 957-965.
Crossref
Crossref
Guey Perng & Kulkanya Chokephaibulkit. (2013) Immunologic hypo- or non-responder in natural dengue virus infection. Journal of Biomedical Science 20:1, pages 34.
Crossref
Crossref
Rosmari Rodriguez-Roche & Ernest A. Gould. (2013) Understanding the Dengue Viruses and Progress towards Their Control. BioMed Research International 2013, pages 1-20.
Crossref
Crossref
Scott B. Halstead & Stephen J. Thomas. 2013. Vaccines. Vaccines
1042
1051
.
Janet C. Lindow, Nathan Borochoff-Porte, Anna P. Durbin, Stephen S. Whitehead, Kelly A. Fimlaid, Janice Y. Bunn & Beth D. Kirkpatrick. (2012) Primary Vaccination with Low Dose Live Dengue 1 Virus Generates a Proinflammatory, Multifunctional T Cell Response in Humans. PLoS Neglected Tropical Diseases 6:7, pages e1742.
Crossref
Crossref
Simona Zompi & Eva Harris. (2012) Animal Models of Dengue Virus Infection. Viruses 4:1, pages 62-82.
Crossref
Crossref
Anna P. Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Alexander C. Schmidt & Stephen S. Whitehead. (2011) Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29:42, pages 7242-7250.
Crossref
Crossref
Julia Schmitz, John Roehrig, Alan Barrett & Joachim Hombach. (2011) Next generation dengue vaccines: A review of candidates in preclinical development. Vaccine 29:42, pages 7276-7284.
Crossref
Crossref
Anna P. Durbin, Stephen S. Whitehead, Donna Shaffer, Dan Elwood, Kimberli Wanionek, Bhavin Thumar, Joseph E. Blaney, Brian R. Murphy & Alexander C. Schmidt. (2011) A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial. PLoS Neglected Tropical Diseases 5:8, pages e1267.
Crossref
Crossref
Beth-Ann G Coller & David E Clements. (2011) Dengue vaccines: progress and challenges. Current Opinion in Immunology 23:3, pages 391-398.
Crossref
Crossref
Brian R. MurphyStephen S. Whitehead. (2011) Immune Response to Dengue Virus and Prospects for a Vaccine. Annual Review of Immunology 29:1, pages 587-619.
Crossref
Crossref
Anna P. Durbin, Alexander Schmidt, Dan Elwood, Kimberli A. Wanionek, Janece Lovchik, Bhavin Thumar, Brian R. Murphy & Stephen S. Whitehead. (2011) Heterotypic Dengue Infection with Live Attenuated Monotypic Dengue Virus Vaccines: Implications for Vaccination of Populations in Areas Where Dengue Is Endemic. The Journal of Infectious Diseases 203:3, pages 327-334.
Crossref
Crossref
Eiji Konishi. (2011) Issues Related to Recent Dengue Vaccine Development. Tropical Medicine and Health 39:4SUPPLEMENT, pages S63-S71.
Crossref
Crossref
Thomas P. Monath. 2011. Replicating Vaccines. Replicating Vaccines
349
438
.
Amber R. Engel, Alexander A. Rumyantsev, Olga A. Maximova, James M. Speicher, Brian Heiss, Brian R. Murphy & Alexander G. Pletnev. (2010) The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3′ non-coding region of the genome. Virology 405:1, pages 243-252.
Crossref
Crossref
Monika Simmons, Timothy Burgess, Julia Lynch & Robert Putnak. (2010) Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396:2, pages 280-288.
Crossref
Crossref
Suman M. Paranjape & Eva Harris. 2010. Dengue Virus. Dengue Virus
15
34
.
Joseph E. Blaney, Anna P. Durbin, Brian R. Murphy & Stephen S. Whitehead. 2010. Dengue Virus. Dengue Virus
145
158
.
Anna P. Durbin & Stephen S. Whitehead. 2010. Dengue Virus. Dengue Virus
129
143
.
Xia Jin, Olivia Tono Block, Robert Rose & Jacob Schlesinger. (2008) Dengue vaccine development and dengue viral neutralization and enhancement assays. Antiviral Therapy 14:6, pages 739-749.
Crossref
Crossref
Grace K Tan & Sylvie Alonso. (2009) Pathogenesis and prevention of dengue virus infection: state-of-the-art. Current Opinion in Infectious Diseases 22:3, pages 302-308.
Crossref
Crossref
Rebecca WardAndrew D Davidson. (2008) Reverse genetics and the study of dengue virus. Future Virology 3:3, pages 279-290.
Crossref
Crossref
Douglas G. Widman, Tomohiro Ishikawa, Rafik Fayzulin, Nigel Bourne & Peter W. Mason. (2008) Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 26:22, pages 2762-2771.
Crossref
Crossref
Lidice Bernardo, Lisset Hermida, Jorge Martin, Mayling Alvarez, Irina Prado, Carlos López, Rafael Martínez, Rosmari Rodríguez-Roche, Aida Zulueta, Laura Lazo, Delfina Rosario, Gerardo Guillén & María G. Guzmán. (2008) Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Archives of Virology 153:5, pages 849-854.
Crossref
Crossref
Joseph E. BlaneyJr.Jr., Neeraj S. Sathe, Laura Goddard, Christopher T. Hanson, Tammy A. Romero, Kathryn A. Hanley, Brian R. Murphy & Stephen S. Whitehead. (2008) Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3? untranslated region (3?-UTR) or by exchange of the DENV-3 3?-UTR with that of DENV-4. Vaccine 26:6, pages 817-828.
Crossref
Crossref
Douglas G. Widman, Ilya Frolov & Peter W. Mason. 2008.
77
126
.
Joseph E BlaneyJr.Jr., Neeraj S Sathe, Christopher T Hanson, Cai Yen Firestone, Brian R Murphy & Stephen S Whitehead. (2007) Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1. Virology Journal 4:1.
Crossref
Crossref
Stephen S. Whitehead, Joseph E. Blaney, Anna P. Durbin & Brian R. Murphy. (2007) Prospects for a dengue virus vaccine. Nature Reviews Microbiology 5:7, pages 518-528.
Crossref
Crossref